MxA mRNA decrease preceding NAb detection in IFN beta-treated MS patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10360642" target="_blank" >RIV/00216208:11110/17:10360642 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/17:10360642 RIV/00064203:_____/17:10360642 RIV/00064165:_____/17:10360642

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1002/brb3.644/abstract" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1002/brb3.644/abstract</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/brb3.644" target="_blank" >10.1002/brb3.644</a>

Jazyk výsledku

angličtina

Název v původním jazyce

MxA mRNA decrease preceding NAb detection in IFN beta-treated MS patients

Popis výsledku v původním jazyce

Background: Multiple sclerosis (MS) patients treated with interferon beta (IFN) are at risk of a declining response to treatment because of the production of IFN-neutralizing antibodies (NAbs). The expression of Myxovirus resistance protein A (MxA) mRNA is regarded as a marker of IFN bioactivity. Aims: The aim of this study was to analyze the kinetics of MxA mRNA expression during long-term IFN treatment and assess its relationship to NAb production. Methods: A prospective, observational, open-label, non-randomized study was designed in multiple sclerosis patients starting IFN treatment. NAbs and MxA mRNA were monitored every six months. Results: 119 patients were consecutively enrolled and 107 were included in the final analysis. Both the presence of NAbs and a decrease in MxA mRNA below the cut off were revealed in 15 patients, however, in six patients (40%) positivity for NAbs was preceded by the decrease in MxA mRNA. In addition, a further six patients showing a decline in MxA mRNA did not have detectable NAbs. Conclusion: Our data indicate that quantification of MxA mRNA is a more sensitive identifier of loss of IFN efficacy than the NAb positivity.

Název v anglickém jazyce

MxA mRNA decrease preceding NAb detection in IFN beta-treated MS patients

Popis výsledku anglicky

Background: Multiple sclerosis (MS) patients treated with interferon beta (IFN) are at risk of a declining response to treatment because of the production of IFN-neutralizing antibodies (NAbs). The expression of Myxovirus resistance protein A (MxA) mRNA is regarded as a marker of IFN bioactivity. Aims: The aim of this study was to analyze the kinetics of MxA mRNA expression during long-term IFN treatment and assess its relationship to NAb production. Methods: A prospective, observational, open-label, non-randomized study was designed in multiple sclerosis patients starting IFN treatment. NAbs and MxA mRNA were monitored every six months. Results: 119 patients were consecutively enrolled and 107 were included in the final analysis. Both the presence of NAbs and a decrease in MxA mRNA below the cut off were revealed in 15 patients, however, in six patients (40%) positivity for NAbs was preceded by the decrease in MxA mRNA. In addition, a further six patients showing a decline in MxA mRNA did not have detectable NAbs. Conclusion: Our data indicate that quantification of MxA mRNA is a more sensitive identifier of loss of IFN efficacy than the NAb positivity.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/NT12385" target="_blank" >NT12385: Sledování exprese mRNA MxA jako markeru biologické účinnosti interferonů ß u pacientů s roztroušenou sklerózou</a><br>

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Brain and Behavior

ISSN

2162-3279

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

4

Strana od-do

—

Kód UT WoS článku

000397564200015

EID výsledku v databázi Scopus

2-s2.0-85012889381